Top 5 Stocks to Buy Now
→ Goldman Sachs just told you what to buy (most people missed it) (From Behind the Markets) (Ad)tc pixel
LON:4BB

4basebio Final Earnings Report

4basebio logo
GBX 550 +25.00 (+4.76%)
As of 06/19/2026 11:49 AM Eastern
ProfileEarnings HistoryForecast

4basebio EPS Results

Actual EPS
-GBX 0.94
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

4basebio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

4basebio Announcement Details

Quarter
Final
Date
5/27/2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

4basebio Earnings Headlines

4basebio Sets Investor Presentation as It Advances Synthetic DNA Platform
June 16, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/4basebio-sets-investor-presentation-as-it-advances-synthetic-dna-platform?utm_source=marketbeat.com&utm_medium=referral
4basebio Plc - 4basebio Appoints Dr. Jeff Coller to Strategic Advisory Board
June 15, 2026  |  uk.finance.yahoo.comhttps://uk.finance.yahoo.com/news/4basebio-plc-4basebio-appoints-dr-060000825.html
Why this tiny stock may move before the SpaceX IPO drops
The projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillion in stored capital will be looking for a home when it does. But the real opportunity isn't the IPO itself. Jovine has identified a small-cap supplier trading near $4 that sits directly in the path of xAI's Colossus infrastructure buildout - and a specific trigger in the S-1 could reprice it overnight.tc pixel
June 21 at 1:00 AM  |  Behind the Markets (Ad)
4basebio appoints Johns Hopkins RNA expert to advisory board
June 15, 2026  |  uk.finance.yahoo.comhttps://uk.finance.yahoo.com/news/4basebio-appoints-johns-hopkins-rna-063200549.html
4basebio (LON:4BB) Shares Down 0.2% - Here's Why
June 13, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30836104
4basebio CEO Increases Stake with Market Purchase of Ordinary Shares
May 22, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/4basebio-ceo-increases-stake-with-market-purchase-of-ordinary-shares?utm_source=marketbeat.com&utm_medium=referral
See More 4basebio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like 4basebio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on 4basebio and other key companies, straight to your email.

About 4basebio

4basebio (LON:4BB) is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients. Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients. These products and technologies are also available for customers and partners with whom we endeavor to combine our capabilities and know-how to develop gene therapy solutions for clinical development and commercialisation.

View 4basebio Profile
Earnings Tools